{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:26Z","timestamp":1761513926000},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bestpracticeobgyn.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.bpobgyn.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T19:03:48Z","timestamp":1482087828000},"page":"105-110","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids"],"prefix":"10.1016","volume":"40","author":[{"given":"Philippe","family":"Bouchard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Chabbert-Buffet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2016.12.002_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/09513590.2014.950647","article-title":"Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology and gynecology","volume":"30","author":"Bouchard","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone modulators in reproductive medicine: pharmacology, clinical efficacy and safety","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.mce.2012.02.021","article-title":"The imminent dawn of SPRM in Obsetrics and Gynecology","volume":"358","author":"Chabbert Buffet","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"suppl 3","key":"10.1016\/j.bpobgyn.2016.12.002_bib4","first-page":"117","article-title":"The development of mifepristone : a pharmaceutical drama in three acts","volume":"55","author":"Ulmann","year":"2000","journal-title":"J\u00a0Am Med Women\u2019s Assoc"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/scientificamerican0690-42","article-title":"RU 486","volume":"262","author":"Ulmann","year":"1990","journal-title":"Sci Am"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib6","first-page":"513","article-title":"Yen SS regression of uterine leiomyomata in response to the antiprogesterone RU 486","author":"Murphy","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/er.2005-0001","article-title":"Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis","volume":"26","author":"Chwalisz","year":"2005","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib8","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/oxfordjournals.humrep.a136283","article-title":"Failure of oestrogen induced LH surge in women treated with mifepristone (RU 486) everyday for 30 days","volume":"10","author":"Baird","year":"1995","journal-title":"Human Reprod"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(10)60101-8","article-title":"Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis","volume":"375","author":"Glasier","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib10","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Uterine Fibroids","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.fertnstert.2014.07.1238","article-title":"Fibroid growth and medical options for treatment","volume":"102","author":"Chabbert Buffert","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib12","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1210\/jc.2006-2816","article-title":"Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary- ovarian axis and endometrium in normal women: a prospective randomized, placebo-controlled trial","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"UPA vs placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"UPA vs Leuprolide Acetate for fibroid treatment","volume":"366","author":"Donnez","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/PGP.0b013e318251035b","article-title":"Endometrial morphology after treatment of uterine fibroids with the SPRM UPA","volume":"31","author":"Williams","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib16","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long term treatment of uterine fibroids with UPA. Pearl III and Pearl III extension study","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of UPA in uterine fibroids Efficacy and safety of repeated use of ulipristal acetate. Pearl IV study","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long term management of uterine fibroids with UPA","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib19","article-title":"Uterine fibroid management : from present to future","volume":"27","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update Epub"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/14728222.2016.1180368","article-title":"Selective PRM: progesterone receptor action, mode of action on the endometrium, and treatment options in gynaecological therapies","author":"Wagenfeld","year":"2016","journal-title":"Exp Opin Ther Targets"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata","volume":"22","author":"Williams","year":"2007","journal-title":"Human Reprod"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bpobgyn.2015.11.012","article-title":"Abnormal Uterine Bleeding","volume":"34","author":"Whitaker","year":"2016","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib23","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3109\/09513590.2012.638754","article-title":"Current and future medical treatment for menometrorrhagia during the premenopause","volume":"27","author":"Bouchard","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.bpobgyn.2016.12.002_bib24","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1210\/jc.2008-0731","article-title":"Persistence of an intact endometrial matrix and vessels structure in women exposed to VA-2914, a Selective progesterone receptor modulator","volume":"93","author":"Ravet","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693416301432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693416301432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T19:58:15Z","timestamp":1536177495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693416301432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":24,"alternative-id":["S1521693416301432"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.12.002","relation":{},"ISSN":["1521-6934"],"issn-type":[{"type":"print","value":"1521-6934"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The history and use of the progesterone receptor modulator ulipristal acetate for heavy menstrual bleeding with uterine fibroids","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}